Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

The Cleveland Clinic: Clinical Trials & FDA Approval Profile

The Cleveland Clinic (Global / Institutional) sponsors 25 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 11 active protocols (7 recruiting now), 11 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.0%
Median Closed Enrollment vs National (145 pts)47 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for The Cleveland Clinic
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)25
Active Pipeline (Recruiting Now)11 (7)
Completed vs Stopped Early11 / 3 (12.0%)
Median Closed Actual Enrollment47 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With The Cleveland Clinic
Hospital Research SiteLocationShared Protocols
Cleveland ClinicCleveland, OH18
Cleveland Clinic FloridaWeston, FL4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by The Cleveland Clinic
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03910244Pomalidomide for the Treatment of Bleeding in HHTPhase IICOMPLETED

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Cleveland Clinic across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the The Cleveland Clinic Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI